BioVersys Granted FDA Fast Track Designation for BV100 in Carbapenem-Resistant Acinetobacter Pneumonia
核心洞察
The U.S. FDA granted Fast Track Designation to BV100, BioVersys' lead clinical asset, for treating VABP and HABP caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (搜索) (CRABC).
BV100 is a novel intravenous formulation of rifabutin that uses the siderophore pathway to target the RNA-polymerase (搜索) enzyme in Gram-negative bacteria, offering a non-β-lactam therapy option.
The designation follows a Phase 2 study showing a 50% reduction in mortality versus best available therapy, with BV100 now in a pivotal Phase 3 trial (RIV-TARGET).
BioVersys AG (SIX: BIOV), a multi-asset, clinical-stage biopharmaceutical company based in Basel, Switzerland, announced on September 2, 2026 that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BV100, its lead clinical asset, for the treatment of ventilator-associated bacterial pneumonia (搜索) (VABP) and hospital-acquired bacterial pneumonia (搜索) (HABP) caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (搜索) (CRABC).
The designation was granted under the Qualified Infectious Disease Product (QIDP) designation, which BV100 first received in May 2019. With Fast Track status, BioVersys gains access to more frequent interactions with the FDA, increased communication on clinical trial design and data requirements, and eligibility for rolling review.
A Novel Non-β-Lactam Mechanism Against a Critical Pathogen
BV100 is a novel intravenous formulation of the antibiotic rifabutin, developed specifically to target severe CRABC infections. The drug possesses a novel mode of action via uptake through the siderophore pathway in Acinetobacter, providing a much-needed non-β-lactam therapy for this infection. For the first time, BV100 allows for the targeting of the RNA-polymerase (搜索) enzyme in Gram-negative bacteria with a human-suitable dose.
CRABC is a major cause of healthcare-associated infections and one of the most challenging multidrug-resistant pathogens to treat, with mortality rates reaching 50% globally. It is classified as a WHO priority-1 critical pathogen. Acinetobacter baumannii calcoaceticus complex (ABC) are Gram-negative bacteria that typically infect critically ill and immunocompromised patients, resulting in severe pneumonia and bloodstream infections. Carbapenem-resistance and multi-drug resistance (MDR) rates for ABC are among the highest recorded for any bacteria in current times (The Lancet 2022; 399: 629–55). BioVersys forecasts the annual number of carbapenem-resistant A. baumannii infections in hospitals to have surpassed one million globally.
Clinical Development Program
BV100 is currently studied in two clinical trials: the pivotal Phase 3 global registrational trial, RIV-TARGET, and the open-label Phase 2b differentiation trial, RIV-CARE, conducted in collaboration with ADVANCE-ID. These studies follow a successful Phase 2 study that showed BV100 achieved an overall 50% reduction in mortality compared with best available therapy.
Dr. Marc Gitzinger, CEO of BioVersys, said: "We are pleased that the US FDA has granted Fast Track designation to BV100, our lead clinical asset. This designation underscores the significant unmet medical need for new treatment options for patients suffering from serious infections caused by multidrug-resistant Acinetobacter baumannii and supports our efforts to bring BV100 to patients as efficiently as possible."
Addressing an Escalating Global Threat
Incidence and resistance rates for ABC are trending upwards, a situation exacerbated significantly by COVID-19. Given the limited treatment options available, such infections carry high mortality rates of up to 50%. The Fast Track designation reflects the urgent need for novel and innovative antimicrobials targeting serious infections caused by Gram-negative bacteria.
BioVersys' most advanced research and development programs address nosocomial infections of Acinetobacter baumannii (BV100, Phase 3) and tuberculosis (alpibectir, Phase 2, in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille, France). The company's candidates are derived from its two internal technology platforms, TRIC and Ansamycin Chemistry, designed to overcome resistance mechanisms, block virulence production, and directly affect the pathogenesis of harmful bacteria.